Incyte, Drug Prices & Medicare Spending
Incyte manufactures 3 drugs tracked by Medicare Part D with total spending of $3.1B.
Incyte Drugs, Ranked by Medicare Spending
| # | Drug | Generic Name | Cost/Claim | Generic? |
|---|---|---|---|---|
| 1 | Jakafi | Ruxolitinib | $11,432.00 | No |
| 2 | Opzelura | Ruxolitinib (topical) | $375.00 | Yes |
| 3 | Pemazyre | Pemigatinib | $20,500.00 | Yes |
Frequently Asked Questions
Incyte manufactures 3 drugs tracked by Medicare Part D, with total annual spending of $3.1B.
Pemazyre (Pemigatinib) is the most expensive at $20,500.00 per claim.
2 of 3 Incyte drugs (67%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.
this entity is one of the data points covered by this site’s U.S. Medicare prescription-drug pricing dataset. The detail above comes directly from CMS Medicare Part D Drug Spending data; the context that follows situates the headline numbers against the broader distribution across U.S. prescription drugs.
Every number on this page links back to CMS Medicare Part D Drug Spending data; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. prescription drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.
Source: CMS Medicare Part D Spending, 2026.